Abstract:Objective. Anti-mutated citrullinated vimentin (MCV) antibodies have been reported as a fairly sensitive serological marker of rheumatoid arthritis (RA). We evaluated the diagnostic value of anti-MCV in a large cohort of Chinese patients with early RA. Methods. One hundred seventy patients with early RA (< 1 yr duration), 66 with other rheumatic diseases, 10 with infectious diseases, and 60 healthy individuals were included in our study. Serum anti-MCV and second-generation anti-cyclic citrullinated peptide antibodies (anti-CCP2) were measured by ELISA, and rheumatoid factor (RF) was measured by rate nephelometry. The associated clinical data of patients with early RA were also evaluated. Then disease activity was scored by the formula for Disease Activity Score (DAS)28, and the degree of radiological changes was assessed by Sharp score. Results. The prevalence of serum anti-MCV in patients with early RA (78.2%, 133/170) was significantly higher than that of other rheumatologic patients and patients with infectious diseases. It was 12% (3/25) in systemic lupus erythematosus, 9.5% (2/21) in primary Sjogren's syndrome, 10% (1/10) in systemic sclerosis, 20% (2/10) in ankylosing spondylitis, 12.5% (1/8) in viral hepatitis type B, and 0% (0/2) in tuberculosis. Anti-MCV was not found in the serum of healthy subjects. The sensitivities of anti-MCV, anti-CCP2, and RF tests for early RA were 78.2%, 61.8%, and 72.4%, respectively, and the specificities were 93.4%, 96.3%, and 80.1%. The combination of anti-MCV and anti-CCP2 positivity showed a very high specificity (97.8%) and positive predictive value (97.1%), anti but a low sensitivity (58.8%). The sensitivity reached 81.2% when the union of anti-MCV and anti-CCP2 positivities was used as one combined criterion. Statistically, anti-MCV had significant correlation with anti-CCP2 (r = 0.587, p = 0.01, 2-tailed) and RF (r = 0.389, p = 0.01, 2-tailed). In addition. it had an interesting correlation with radiological assessment (r = 0.349 p = 0.05, 2-tailed). The anti-MCV had no significant correlation with other factors, such as erythrocyte sedimentation rate, C-reactive protein, antikeratin antibody, antiperinuclear factor, global visual analog scale score for joint pain, IgA, IgG, 1(,M, C3, C4, hidden rheumatoid factor for IgA (HRFIA), HRFIgG, and DAS28. Conclusion. Anti-MCV is a novel diagnostic marker for early RA. It may be more useful if the anti-CCP2 assay is performed concomitantly to diagnose patients with early RA. (First Release May 15 2009: J Rheumatol 2009;36:1136-42; doi: 10.3899/jrhewn.080796)

Predictive Value of Anti-Mutated Citrullinated Vimentin Antibody on One-Year Radiographic Progression in Patients with Rheumatoid Arthritis

The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.

Clinical utility of anti-citrullinated peptide antibodies in patients with rheumatoid arthritis

Evaluation of the clinical performance of anti-mutated citrullinated vimentin antibody and 14-3-3 eta testing in rheumatoid arthritis

The value of pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) in early rheumatoid arthritis(RA)

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies

Diagnosis and Application of Combine Detection on Pyridine Cross-linked Comprehensive Peptide of Type Ⅰ Collagen,Matrix Metalloproteinase Enzyme-3 Projects,CCP and RF in Patients with Early Rheumatoid Arthritis

Early Prediction of Rheumatoid Arthritis by Magnetic Resonance Imaging in the Absence of Anti-Cyclic Citrullinated Peptide Antibodies and Radiographic Erosions in Undifferentiated Inflammatory Arthritis Patients: A Prospective Study

Value of Serum Collagen Triple Helix Repeat Containing-1(Cthrc1) and 14-3-3η Protein Compared to Anti-Ccp Antibodies and Anti-Mcv Antibodies in the Diagnosis of Rheumatoid Arthritis

Association of anti-cyclic citrullinated peptide antibody with treatment target achierement and flare in patients with rheumatoid arthritis

Identification of early risk factors for anti-citrullinated-protein-antibody positive rheumatoid arthritis—a prospective cohort study

Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis.

Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals

Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test

Prediction of Future Rheumatoid Arthritis in Chinese Patients with Early Arthritis: an Effective Way of Patient Care

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies

Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis

Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Comment on 'baseline Serum Level of Matrix Metalloproteinase-3 As a Biomarker of Progressive Joint Damage in Rheumatoid Arthritis Patients'

Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis